Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Savant Capital LLC

Savant Capital LLC decreased its holdings in Edwards Lifesciences Co. (NYSE:EW) by 29.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,995 shares of the medical research company’s stock after selling 4,542 shares during the quarter. Savant Capital LLC’s holdings in Edwards Lifesciences were worth $814,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. Wellington Management Group LLP raised its stake in Edwards Lifesciences by 86.3% in the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after acquiring an additional 14,610,123 shares during the last quarter. Jennison Associates LLC purchased a new position in Edwards Lifesciences in the 4th quarter worth $555,939,000. Assenagon Asset Management S.A. raised its stake in Edwards Lifesciences by 475.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock worth $314,182,000 after acquiring an additional 3,506,886 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its stake in Edwards Lifesciences by 239.9% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company’s stock worth $243,745,000 after acquiring an additional 2,606,950 shares during the last quarter. Finally, Seilern Investment Management Ltd purchased a new position in Edwards Lifesciences in the 4th quarter worth $109,490,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on EW. Robert W. Baird reduced their target price on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Truist Financial reiterated a “hold” rating and set a $78.00 price objective (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. The Goldman Sachs Group lifted their price objective on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. Barclays lifted their price objective on Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday. Finally, Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $82.00 to $90.00 in a research note on Monday, December 16th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $79.95.

Edwards Lifesciences Trading Up 0.3 %

EW stock opened at $76.23 on Friday. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The stock has a market cap of $44.96 billion, a price-to-earnings ratio of 11.00, a PEG ratio of 3.64 and a beta of 1.10. The business’s 50-day moving average is $72.67 and its 200 day moving average is $69.50.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. On average, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the sale, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Steven R. Loranger sold 5,739 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the sale, the director now directly owns 60,372 shares in the company, valued at approximately $4,613,628.24. The trade was a 8.68 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 26,489 shares of company stock worth $2,002,829 in the last ninety days. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.